NTRK1 and prostate cancer: Doxazosin treatment resulted in activation of the pro-apoptotic receptor tyrosine kinase EphA2 and associated degradation of EphA2 that is characteristic to activated receptor tyrosine kinases, consistent with data obtained from prostate cancer (PC3) and breast cancer (MDA-MB-231) cells [27].